Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Literature DB >> 28838994

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Anna Vidal-Crespo¹, Vanina Rodriguez^1,2, Alba Matas-Cespedes^1,2, Eriong Lee^1,2, Alfredo Rivas-Delgado³, Eva Giné^2,3, Alba Navarro^1,2, Sílvia Beà^1,2, Elias Campo^1,2,4, Armando López-Guillermo^2,3, Monica Lopez-Guerra^1,2,4, Gaël Roué^1,2,5, Dolors Colomer^1,2,4, Patricia Pérez-Galán^6,2.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28838994 PMCID： PMC5664406 DOI： 10.3324/haematol.2017.168930

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

14 in total

1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors: Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal: Proc Natl Acad Sci U S A Date: 2010-07-06 Impact factor: 11.205

2. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

Authors: David J J de Gorter; Esther A Beuling; Rogier Kersseboom; Sabine Middendorp; Janine M van Gils; Rudolf W Hendriks; Steven T Pals; Marcel Spaargaren
Journal: Immunity Date: 2007-01 Impact factor: 31.745

3. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Authors: Rami Rahal; Mareike Frick; Rodrigo Romero; Joshua M Korn; Robert Kridel; Fong Chun Chan; Barbara Meissner; Hyo-eun Bhang; Dave Ruddy; Audrey Kauffmann; Ali Farsidjani; Adnan Derti; Daniel Rakiec; Tara Naylor; Estelle Pfister; Steve Kovats; Sunkyu Kim; Kerstin Dietze; Bernd Dörken; Christian Steidl; Alexandar Tzankov; Michael Hummel; John Monahan; Michael P Morrissey; Christine Fritsch; William R Sellers; Vesselina G Cooke; Randy D Gascoyne; Georg Lenz; Frank Stegmeier
Journal: Nat Med Date: 2013-12-22 Impact factor: 53.440

4. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Authors: Erica K Evans; Richland Tester; Sharon Aslanian; Russell Karp; Michael Sheets; Matthew T Labenski; Steven R Witowski; Heather Lounsbury; Prasoon Chaturvedi; Hormoz Mazdiyasni; Zhendong Zhu; Mariana Nacht; Martin I Freed; Russell C Petter; Alex Dubrovskiy; Juswinder Singh; William F Westlin
Journal: J Pharmacol Exp Ther Date: 2013-05-24 Impact factor: 4.030

5. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

Authors: Nakhle S Saba; Delong Liu; Sarah E M Herman; Chingiz Underbayev; Xin Tian; David Behrend; Marc A Weniger; Martin Skarzynski; Jennifer Gyamfi; Lorena Fontan; Ari Melnick; Cliona Grant; Mark Roschewski; Alba Navarro; Sílvia Beà; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Adrian Wiestner
Journal: Blood Date: 2016-04-28 Impact factor: 22.113

6. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.

Authors: A Moros; V Rodríguez; I Saborit-Villarroya; A Montraveta; P Balsas; P Sandy; A Martínez; A Wiestner; E Normant; E Campo; P Pérez-Galán; D Colomer; G Roué
Journal: Leukemia Date: 2014-03-18 Impact factor: 11.528

7. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Authors: Betty Y Chang; Michelle Francesco; Martin F M De Rooij; Padmaja Magadala; Susanne M Steggerda; Min Mei Huang; Annemieke Kuil; Sarah E M Herman; Stella Chang; Steven T Pals; Wyndham Wilson; Adrian Wiestner; Marcel Spaargaren; Joseph J Buggy; Laurence Elias
Journal: Blood Date: 2013-08-12 Impact factor: 22.113

8. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors: Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245

9. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.

Authors: Yulia N Demchenko; Leslie A Brents; Zhihong Li; Leif P Bergsagel; Lawrence R McGee; Michael W Kuehl
Journal: Oncotarget Date: 2014-06-30

Review 10. Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors: Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal: Nat Rev Cancer Date: 2014-04 Impact factor: 60.716

7 in total

1. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Authors: Chiara Tarantelli; Lu Zhang; Elisabetta Curti; Eugenio Gaudio; Filippo Spriano; Valdemar Priebe; Luciano Cascione; Alberto J Arribas; Emanuele Zucca; Davide Rossi; Anastasios Stathis; Francesco Bertoni
Journal: Haematologica Date: 2019-01-24 Impact factor: 9.941

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

2. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

3. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

4. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

5. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

6. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.

7. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

8. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

9. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.

Review 10. Targeting Bruton's tyrosine kinase in B cell malignancies.

1. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Review 2. Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.

Review 3. Pemphigus: Current and Future Therapeutic Strategies.

4. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.

Review 5. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.

Review 6. The Therapeutic Potential of Targeting NIK in B Cell Malignancies.

Review 7. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.